In this context, there are already readily available and numerous amounts of drugs that act in the RAS and can be used in the therapeutic measures of dementias, especially AD, like ARBs that work through the unopposed action of ANGII on AT2 receptors, because as the AT1 receptor is blocked, these drugs increase the concentration of ANGII to act on the AT2 receptor16. Here, AGTR1 is linked to Alzheimer disease.